Press Releases

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evaluating a novel combination therapy for patients with locally advanced or metastatic urothelial carcinoma (mUC), including bladder cancer, and represents an important step forward in 4D Path’s mission to redefine precision oncology.

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

Baylor Genetics Supports Bipartisan House Bill to Broaden Medicaid Access to Genomic Sequencing for Children who Meet Medical Criteria

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, announced its support for the Genomic Answers for Children’s Health Act. This legislation, introduced in the House of Representatives with bipartisan support, aims to improve access to genomic sequencing by clarifying that such testing is covered under Medicaid’s “Early and Periodic Screening, Diagnostic, and Treatment Services” for children meeting certain clinical criteria.

ELRIG Announces Drs Stephen Ward and Annarita Miccio as Keynote Speakers for Cell and Gene Therapy 2026

• Inaugural event takes place from 9–10 March at Hinxton Hall in Cambridge, UK • Programme spans neurological disorders, sensory diseases, rare conditions, and cancer immunotherapy

CluePoints Appoints New Chief People Officer to Support Next Phase of Global Growth

CluePoints, provider of leading statistical and AI-driven software solutions, has appointed Sinead Godkin as its new Chief People Officer (CPO).

Gifthealth Announces Jeremy Richardson as New Chief Commercial Officer

Gifthealth has announced the appointment of Jeremy Richardson as its new Chief Commercial Officer (CCO).

Astoriom Appoints Will Edwards as Chief Executive Officer

Strategic appointment to support global scale-up of sample management operations

Firstsource Acquires TeleMedik

Cycle Pharmaceuticals and Inceptua Group Expand the Free Goods Programme for Patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU) to Include Morocco and Egypt

Cycle and Inceptua have announced the expansion of their partnership to make NITYR® tablets available via a Free Goods Programme for eligible patients with HT-1 and AKU to include Morocco and Egypt.

Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 Months

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

PharmaForceIQ Acquires Aktana to Deliver Unparalleled Cross-Functional Engagement Impact for Pharma

PharmaForceIQ has announced its acquisition of Aktana, aligning its cutting-edge digital orchestration platform with the industry’s premier AI-driven field Next-Best-Action (NBA) platform.

Northwell Health and START Center for Cancer Research unveil world-class early-phase cancer clinical trial center

The first START site in New York launches a new strategic partnership to provide cutting-edge cancer research.

eClinical Solutions Unveils AI Agents to Power the Next Era of Clinical Data Automation

Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions

CluePoints Scoops Prestigious 2025 Scrip Award

CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.

4D Path Collaborates with AMD and Oracle to Scale Predictive Oncology

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.

New York Gastroenterology Associates Taps Proscia for Digital Pathology

New York Gastroenterology Associates, LLP (NYGA), New York City’s leading independent gastroenterology practice, is working with Proscia, a pathology AI company, to advance its standard of excellence

New Scale Announces Availability of new DART linear actuator and stage platform

New Scale Technologies is announcing the availability of the new DART linear actuator and stage platform. The DART line is designed to meet the needs of photonic instruments and life science companies looking for smart motion solutions with longer travel and lower cost for high-volume applications. The DART Smart Linear Actuator builds on New Scale’s proprietary SQUIGGLE® technology, offering a greater range of motion and higher force.

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.

Proscia Achieves SOC 2 Type II Certification, Strengthening Enterprise Trust

Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale